135 related articles for article (PubMed ID: 21273553)
21. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
22. VEGF-initiated angiogenesis and the uPA/uPAR system.
Breuss JM; Uhrin P
Cell Adh Migr; 2012; 6(6):535-615. PubMed ID: 23076133
[TBL] [Abstract][Full Text] [Related]
23. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
24. Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils.
Pluskota E; Soloviev DA; Bdeir K; Cines DB; Plow EF
J Biol Chem; 2004 Apr; 279(17):18063-72. PubMed ID: 14769799
[TBL] [Abstract][Full Text] [Related]
25. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
Ellis V; Behrendt N; Danø K
J Biol Chem; 1991 Jul; 266(19):12752-8. PubMed ID: 1829461
[TBL] [Abstract][Full Text] [Related]
27. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
29. Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.
Kreiling JL; Montgomery MA; Wheeler JR; Kopanic JL; Connelly CM; Zavorka ME; Allison JL; Macdonald RG
FEBS J; 2012 Aug; 279(15):2695-713. PubMed ID: 22681933
[TBL] [Abstract][Full Text] [Related]
30. The role of plasminogen in angiogenesis in vivo.
Oh CW; Hoover-Plow J; Plow EF
J Thromb Haemost; 2003 Aug; 1(8):1683-7. PubMed ID: 12911578
[TBL] [Abstract][Full Text] [Related]
31. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
32. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
Pliyev BK; Antonova OA; Menshikov M
Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
34. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
35. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
36. The mannose 6-phosphate/insulin-like growth factor 2 receptor mediates plasminogen-induced efferocytosis.
Ohradanova-Repic A; Machacek C; Donner C; Mühlgrabner V; Petrovčíková E; Zahradníková A; Vičíková K; Hořejší V; Stockinger H; Leksa V
J Leukoc Biol; 2019 Mar; 105(3):519-530. PubMed ID: 30657605
[TBL] [Abstract][Full Text] [Related]
37. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
38. The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration.
Leksa V; Godár S; Cebecauer M; Hilgert I; Breuss J; Weidle UH; Horejsí V; Binder BR; Stockinger H
J Biol Chem; 2002 Oct; 277(43):40575-82. PubMed ID: 12189157
[TBL] [Abstract][Full Text] [Related]
39. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
40. Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer.
Conforti G; Dominguez-Jimenez C; Rønne E; Høyer-Hansen G; Dejana E
Blood; 1994 Feb; 83(4):994-1005. PubMed ID: 8111067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
